MEDIA CENTER

Finance & Economics Network | Frost & Sullivan: Going public is no longer the end point of innovation but a new beginning for biotech companies
Previously, the registration-based system reform has been piloted on the Sci-tech Innovation Board, Growth Enterprise Market, and Beijing Stock Exchange. The pharmaceutical and health sector has benefited significantly, with capital vitality injecting momentum into the industry. In particular, the g
Explore more
Financial Programs Center of China Media Group | Frost & Sullivan: Accelerating the Promotion of Robot Applications to Empower Transformation and Upgrading across All Industries
The Ministry of Industry and Information Technology and 17 other departments recently issued the '“Robot + "Implementation Plan for Application Actions", proposing to deepen key areas of "robots". + "Applications. What is the current popularization rate of robots in domestic manufacturing applicatio
Explore more
21st Century Economic Report | Frost & Sullivan executive: The capital market for innovative drugs is warming up, and pharmaceutical companies need to make long-term arrangements as early as possible with a forward-looking perspective
In the past two years, the financing environment for innovative drugs in China has begun to change, with investors becoming more cautious and calm. How do they view the current capital 'cold winter'? 2023 What changes will occur in the annual investment style? Biopharmaceutical technology innovation
Explore more
Securities Daily | Frost & Sullivan Dr. Wang Xin: With multiple advantages, the attractiveness of the Chinese market to foreign capital will become stronger and stronger
Beijing time 2 month 10 International Indexes Committee MSCI The quarterly audit change results were announced. Among them, MSCI China Indexes Newly Included 12 Only Chinese stocks, excluding 6 only; MSCIA The onshore equity index has increased. 10 Only constituent stocks, excluding 5 Only constitue
Explore more
CBN Finance | Frost & Sullivan: Currently, there are over 60 ADC drugs in clinical development in China, which will continue to attract attention in the future
Recently, Northeast Pharmaceutical disclosed that in order to accelerate the advancement of its collaboration with the United States MedAbome company ADC Medications and CAR-T The subsidiary established through the implementation of the cell therapy technology cooperation project has completed its i
Explore more
Securities Daily | Frost & Sullivan: It is expected that the supply-demand gap in the civil shipbuilding industry will continue to widen, driving the industry towards a state of both volume and price increases
According to the latest news from CCTV.com, 2022 In [year], China's international market share in the shipbuilding industry continued to rank first globally. In terms of tonnage delivered, new orders placed, and orders in hand, they accounted for 47.3% , 55.2% and 49.8% Among the global new ship ord
Explore more
Securities Daily | Frost & Sullivan: Expecting robust growth in sectors such as electronics, power equipment, and pharmaceutical biotechnology
As of 1 month 30 days, a total of 1,209 Public disclosure of listed companies 2022 Annual performance forecast 664 Domestic performance is expected to be positive, proportionally 55% Specifically, 442 The company's performance is expected to increase. 105 The number of households has increased sligh
Explore more
Caixin Business News | Frost & Sullivan: The Chinese game market has moved from an era of extensive volume buying to one of building a high-quality game moat, and the localization process for game developers still has a long way to go
1 In mid-month, the Game Working Committee of the Chinese Audio-Visual Games Industry Association (hereinafter referred to as 'Game Working Committee') announced 2022 China's Game Industry Data Summary for 8 Among market indicators, only the client game market has seen growth. Both the market scale
Explore more
Blue Whale Finance | Frost & Sullivan: Anti-tumor drugs remain the biggest category in healthcare insurance negotiations, with rare diseases and COVID-19 drugs entering the scope of healthcare insurance to improve patient accessibility
1 month 18 On the same day, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security officially issued the 'National Essential Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug List'. (2022 year ) 》(hereinafter referred to a
Explore more
lilac garden | Frost & Sullivan executive: The pharmaceutical industry is returning to warmth in 2023, with three major areas worthy of attention
In recent years, traditional generic drug companies have seen a decline in performance under the impact of centralized procurement. At the same time, there has also been a significant transformation in the domestic innovation drug environment. Biotech The difficulty of financing has increased, and t
Explore more
